ArticleFrontiers in immunology2021

Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.

Thais G Moreira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.